From trials to clinical practice: Temporal trends in the coverage of specialized allied health services for Parkinson's disease

被引:5
|
作者
Bloem, Bastiaan R. [1 ]
Eimers, Marietta [1 ]
van Galen, Mirte S. [2 ]
Munneke, Marten [1 ]
Darweesh, Sirwan K. L. [1 ,3 ]
机构
[1] Radboud Univ Nijmegen, Donders Inst Brain, Dept Neurol Cognit & Behav, Med Ctr, Nijmegen, Netherlands
[2] Vektis CV, Zeist, Netherlands
[3] Erasmus MC Univ Med Ctr, Dept Epidemiol, Rotterdam, Netherlands
关键词
disorders; movement disorders; neurological; Parkinson' s disease; scaling of healthcare innovations; specialized allied health services; OCCUPATIONAL-THERAPY; CARE;
D O I
10.1111/ene.14627
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and purpose To determine how the coverage of specialized allied health services for patients with Parkinson's disease (PD) has developed in the Netherlands since the publication of trials that demonstrated cost-effectiveness. Methods We used healthcare expenditure-based data on all insured individuals in the Netherlands to determine the annual proportion of patients with PD who received either specialized or generic allied health services (physiotherapy, occupational therapy, speech-language therapy) in 2 calendar years separated by a 5-year interval (2012 and 2017). Specialized allied health services were delivered through the ParkinsonNet approach, which encompassed professional training and concentration of care among specifically trained professionals. Results Between 2012 and 2017, there was an increase in the number of patients with any physiotherapy (from 17,843 [62% of all patients with PD that year] to 22,282 [68%]), speech-language therapy (from 2171 [8%] to 3378 [10%]), and occupational therapy (from 2813 [10%] to 5939 [18%]). Among therapy-requiring patients, the percentage who were treated by a specialized therapist rose substantially for physiotherapy (from 36% in 2012 to 62% in 2017; chi(2) = 2460.2; p < 0.001), speech-language therapy (from 59% to 85%; chi(2) = 445.4; p < 0.001), and occupational therapy (from 61% to 77%; chi(2) = 231.6; p < 0.001). By contrast, the number of patients with generic therapists did not change meaningfully. By 2017, specialized care delivery had extended to regions that had been poorly covered in 2012, essentially achieving nationwide coverage. Conclusions Following the publication of positive trials, specialized allied healthcare delivery was successfully scaled for patients with PD in the Netherlands, potentially serving as a template for other healthcare innovations for patients with PD elsewhere.
引用
收藏
页码:775 / 782
页数:8
相关论文
共 50 条
  • [41] Sudden unexpected death in Parkinson's disease: Insights from clinical practice
    Scorza, Fulvio A.
    Guimaraes-Marques, Marcia
    Nejm, Mariana
    de Almeida, Antonio Carlos G.
    Scorza, Carla A.
    Fiorini, Ana C.
    Finsterer, Josef
    CLINICS, 2022, 77
  • [42] Apomorphine - pharmacological properties and clinical trials in Parkinson's disease
    Jenner, Peter
    Katzenschlager, Regina
    PARKINSONISM & RELATED DISORDERS, 2016, 33 : S13 - S21
  • [43] Clinical trials aimed at detecting neuroprotection in Parkinson's disease
    Hauser, Robert A.
    Zesiewicz, Theresa A.
    NEUROLOGY, 2006, 66 (10) : S58 - S68
  • [44] The Linked Clinical Trials initiative (LCT) for Parkinson's disease
    Brundin, Patrik
    Wyse, Richard K.
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2019, 49 (03) : 307 - 315
  • [45] Gender representation in nonsurgical clinical trials in Parkinson's disease
    Whitney, CM
    Maddux, BN
    Riley, DE
    NEUROLOGY, 2001, 56 (08) : A375 - A376
  • [46] The impact of placebo assignment in clinical trials of Parkinson's disease
    Goetz, CG
    Janko, K
    Blasucci, L
    Jaglin, JA
    ANNALS OF NEUROLOGY, 2002, 52 (03) : S34 - S34
  • [47] New Clinical Trials for Nonmotor Manifestations of Parkinson's Disease
    Schrag, Anette
    Sauerbier, Anna
    Chaudhuri, Kallol Ray
    MOVEMENT DISORDERS, 2015, 30 (11) : 1490 - 1503
  • [48] Impact of placebo assignment in clinical trials of Parkinson's disease
    Goetz, CG
    Janko, K
    Blasucci, L
    Jaglin, JA
    MOVEMENT DISORDERS, 2003, 18 (10) : 1146 - 1149
  • [49] Patterns of outcome measurement in Parkinson's disease clinical trials
    Mitchell, SL
    Harper, DW
    Lau, A
    Bhalla, R
    NEUROEPIDEMIOLOGY, 2000, 19 (02) : 100 - 108
  • [50] Results of clinical trials of tiprolisant in narcolepsy and Parkinson's disease
    Arnulf, I.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 : S204 - S204